Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome
NCT ID: NCT00035867
Last Updated: 2008-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
65 participants
INTERVENTIONAL
2002-04-30
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TLK199 HCl Liposomes for Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate liver and kidney function
* Ineligible for, or refusing, allogeneic bone marrow transplant
* At least 18 years of age
* Discontinuation of growth factors (e.g., G- CSF) at least 2 weeks prior to study entry
Exclusion Criteria
* Pregnant or lactating women
* History of allergy to eggs
* Other investigational drugs within 14 days of study entry
* Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry
* Concomitant steroids or hormones for the treatment of neoplasms
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Telik
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
The Angeles Clinic & Research Institute
Los Angeles, California, United States
University of Chicago
Chicago, Illinois, United States
Midwest Cancer Research Group
Skokie, Illinois, United States
Oregon Health & Science University
Portland, Oregon, United States
The Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Texas Cancer Associates
Dallas, Texas, United States
M.D. Anderson Cancer Center
Houston, Texas, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H 3rd, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol. 2009 May 13;2:20. doi: 10.1186/1756-8722-2-20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TLK199.1001
Identifier Type: -
Identifier Source: org_study_id